HLA-DQ 3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

No abstract is available for this paper.

• Publication year

  year unknown

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Risk factor analysis of hypersensitivity reactions to abacavir.

  2002cited by this paper
• Eukaryotic heat shock proteins as molecular links in innate and adaptive immune responses: Hsp60-mediated activation of cytotoxic T cells.

  2001cited by this paper
• Toxicity of Antiviral Nucleoside Analogs and the Human Mitochondrial DNA Polymerase*

  2001cited by this paper
• Haplotype tagging for the identification of common disease genes

  2001cited by this paper
• High-resolution haplotype structure in the human genome

  2001cited by this paper
• Metabolic activation in drug allergies.

  2001cited by this paper
• TNFα promoter region gene polymorphisms in carbamazepine-hypersensitive patients

  2001cited by this paper
• Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.

  2001cited by this paper
• Mitochondrial toxicity and HIV therapy

  2001cited by this paper
• Hypersensitivity Related to Abacavir in Two Members of a Family

  2001cited by this paper
• Localization of central MHC genes influencing type I diabetes.

  2001cited by this paper
• T Cells from Allergic Individuals + Reactive Metabolites by Drug-Specific CD 4 Recognition of Sulfamethoxazole and Its

  2000cited by this paper
• Abacavir rechallenge has to be avoided in case of hypersensitivity reaction.

  1999cited by this paper
• HLA-restricted , Processing-and Metabolism-independent Pathway of Drug Recognition by Human ab T Lymphocytes

  1998cited by this paper
• The role of heat shock proteins in the stimulation of an immune response.

  1998cited by this paper
• Trinucleotide repeat polymorphism within exon 5 of the MICA gene (MHC class I chain-related gene A): allele frequency data in the nine population groups Japanese, Northern Han, Hui, Uygur, Kazakhstan, Iranian, Saudi Arabian, Greek and Italian.

  1997cited by this paper
• Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89

  1997cited by this paper
• HLA and disease associations: detecting the strongest association.

  1994cited by this paper
• 5 Studies of MHC haplotypes by pulsed field gel electrophoresis

  1991cited by this paper
• Disease Associations with Complotypes, Supratypes and Haplotypes

  1983cited by this paper
• Ankylosing spondylitis and HL-A 27.

  1973cited by this paper

• Drug hypersensitivity reactions in children in clinical practice: A WAO Statement

  2025cites this paper
• Human Leukocyte Antigens Class II Alleles Affecting the Response to 5–7 Year Antiretroviral Therapy in A Latvian Cohort

  2019cites this paper
• HLA-B*5701 Allele in HIV-infected Indian Children and its Association with Abacavir Hypersensitivity

  2018cites this paper
• Phenotypic and pharmacogenetic evaluation of patients with thiazide-induced hyponatremia. Journal of Clinical Investigation,

  2018cites this paper
• Adverse Cutaneous Drug Eruptions: Review of Immunology, Pathogenesis, and Pharmacogenomics With Focus on HIV and TEN

  2018cites this paper
• Phenotypic and pharmacogenetic evaluation of patients with thiazide-induced hyponatremia

  2017cites this paper
• HLA-DR7 and HLA-DQ2: Transgenic mouse strains tested as a model system for ximelagatran hepatotoxicity

  2017cites this paper
• Effect of Infectious Diseases on the Pathogenesis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

  2017cites this paper
• Pharmacogenomics and adverse drug reactions: Primetime and not ready for primetime tests.

  2016cites this paper
• Personalized medicine: its implications and its impact on patents.

  2015cites this paper
• Pharmacogenetics: transforming clinical medicine

  2012cites this paper
• Peptide binding specificities of HLA-B*5701 and B*5801

  2012cites this paper
• Association of the genetic marker for abacavir hypersensitivity HLA-B*5701 with HCP5 rs2395029 in Mexican Mestizos.

  2011cites this paper
• Prevalence of human leukocyte antigen HLA-B*57:01 in HIV-infected subjects in the Czech Republic.

  2011cites this paper
• Genetische Anfälligkeit für Infektionen

  2011cites this paper
• "The real 'drug-HLA story' started at the beginning of the century with abacavir…"

  2010cites this paper
• Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV

  2010cites this paper
• The Canadian Pharmacogenomics Network for Drug Safety: A Model for Safety Pharmacology

  2010cites this paper
• Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects

  2009cites this paper
• Epilepsy pharmacogenetics.

  2009cites this paper
• Drug hypersensitivity in HIV

  2007cites this paper
• Why do patients fail HIV therapy?

  2007cites this paper
• The Introduction of Pharmacogenetic Screening to HIV Clinical Practice – Potential Benefits and Challenges 13

  2007cites this paper
• Numerous reactions with Epidemiology and Causes of Drug Hypersensitivity

  2007cites this paper
• The pharmacogenetics of antiretroviral therapy

  2006cites this paper
• Overview of the pharmacogenetics of HIV therapy

  2006cites this paper
• Antiretroviral therapy: an update for the non-AIDS specialist

  2005cites this paper
• Can Genetics Predict Efavirenz Central Nervous System Side Effects and Drug Levels ?

  2005cites this paper
• The changing scene of the regulation of medicines in the UK. Paper from The Use of Medicines: Regulation & Clinical Pharmacology in the 21st Century Symposium - December 2003.

  2004cites this paper
• Adverse Drug Effects Differentiating between complicating consequences of

  year unknowncites this paper
• A problem in translating genetic findings into clinical practice is that many associations do not pinpoint a single gene responsible for a biologic effect

  year unknowncites this paper